Statement
-
Statement
Incubate Statement on Amendment 5284 of the Inflation Reduction Act
08.06.2022
Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:
-
Statement
Incubate Letter on Reconciliation Drug Pricing Provisions
07.15.2022
Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package
-
Statement
Incubate Statement on Federal Drug Price Provisions
07.06.2022
See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.
-
Statement
Incubate Statement on WTO Decision to Suspend Global IP Rights
06.30.2022
The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.
-
Statement
Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
05.25.2022
Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers
-
Statement
Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
04.14.2022
See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.
-
Statement
Incubate Letter in Opposition to MA S. 2774
04.07.2022
See Incubate's letter to the Massachusetts state legislature in opposition to S. 2774
-
Statement
Incubate Letter in Opposition to CT SB-13
03.29.2022
See Incubate's letter to Connecticut legislature opposing SB-13.
-
Statement
Gaurav Gupta Comment on the Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
02.10.2022
Incubate Advisory Council member Gaurav Gupta's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
Statement
Incubate Comment on the Proposed Decision Memo for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
02.10.2022
Executive Director John Stanford's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
Statement
Moonshot Statement
02.02.2022
Read Incubate Executive Director John Stanford's statement on President BIden's Moonshot initiative.
-
Statement
Leading Venture Capital Group Alarmed By Build Back Better Act’s Prescription Drug Provision
11.19.2021
John Stanford, Executive Director of Incubate, a coalition of America's early-stage life sciences investors, issued the following statement on congressional Democrats' passage of the Build Back Better Act